Unité de Recherche et de Neurostimulation, Centre Hospitalier Esquirol, 15 rue du Docteur Marcland, 87025 Limoges Cedex, France; INSERM, UMR 1094, Neuroépidémiologie Tropicale, Faculté de Médecine, Université de Limoges, 2 avenue Martin Luther King, Limoges, France.
Unité de Recherche et de Neurostimulation, Centre Hospitalier Esquirol, 15 rue du Docteur Marcland, 87025 Limoges Cedex, France.
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110229. doi: 10.1016/j.pnpbp.2020.110229. Epub 2020 Dec 31.
The study of clinically related biological indicators in Major Depression (MD) is important. The Brain Derived Neurotrophic Factor (BDNF) appears to play an important role in MD, through its neurotrophic effect, and its levels are significantly decreased. The variation in the serum levels of its precursor proBDNF, which has opposite effects, is not known. Their distribution between serum and exosomes and their evolution during antidepressant treatment is also not known, and may be important in modulating their effects. The aim of this study is to evaluate whether serum and exosome mBDNF and proBDNF levels are altered in patients with MD during antidepressant treatment compared to controls, and their association with clinical improvement and clinical variables.
42 MD subjects and 40 controls were included. Questionnaires to assess the severity of depression and cognitive impairment and blood samples were collected during the three visits at D0 (inclusion) and 3 and 7 weeks after the start of antidepressant treatment. Assays for mBDNF and proBDNF levels were performed in serum and exosomes by ELISA.
MD subjects had decreased serum and exosomal BDNF levels and increased proBDNF levels at D0 compared to controls. BDNF and pro-BDNF vary in an inverse manner in both serum and exosomes during antidepressant treatment. No relationship of BDNF and proBDNF levels to clinical improvement and depression scales was found.
We demonstrated an evolution of those molecules either in serum or in exosomes after MD treatment. These transport vesicles could have a role in the regulation of BDNF.
研究与重度抑郁症（MD）相关的临床生物标志物很重要。脑源性神经营养因子（BDNF）似乎通过其神经营养作用在 MD 中发挥重要作用，其水平显著降低。其前体 proBDNF 的血清水平变化，其作用相反，目前尚不清楚。它们在血清和外泌体之间的分布及其在抗抑郁治疗过程中的变化也尚不清楚，并且可能在调节其作用方面很重要。本研究旨在评估在抗抑郁治疗期间与对照组相比，MD 患者的血清和外泌体 mBDNF 和 proBDNF 水平是否发生变化，以及它们与临床改善和临床变量的关系。
纳入 42 名 MD 患者和 40 名对照者。在三个就诊时间（D0[纳入]和抗抑郁治疗开始后 3 周和 7 周）收集评估抑郁严重程度和认知障碍的问卷和血样。通过 ELISA 法测定血清和外泌体中 mBDNF 和 proBDNF 水平。
与对照组相比，MD 患者在 D0 时血清和外泌体 BDNF 水平降低，proBDNF 水平升高。在抗抑郁治疗期间，BDNF 和 proBDNF 在血清和外泌体中呈反向变化。未发现 BDNF 和 proBDNF 水平与临床改善和抑郁量表有关。
我们证明了 MD 治疗后这些分子在血清或外泌体中的演变。这些转运囊泡可能在 BDNF 的调节中起作用。
